OPKO Biologics Doses First Participant in Phase 1/2a Trial of Acromegaly Drug
Bitget2026/10/27 12:08- OPKO Health unit OPKO Biologics dosed the first participant in a first-in-human Phase 1/2a trial of OPK-8801001 for acromegaly.
- The trial will assess safety, tolerability and pharmacological activity of the investigational long-acting growth hormone receptor antagonist.
- OPK-8801001 targets once-weekly administration; preclinical studies showed sustained, dose-dependent suppression of insulin-like growth factor-1, a marker of acromegaly activity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
